Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;80(11):3198-3200.
doi: 10.1111/all.16643. Epub 2025 Jul 16.

Delays and Barriers Related to the Treatment of Hereditary Angioedema Attacks in Italy

Mauro Cancian  1 , Pietro Accardo  2 , Francesco Arcoleo  2 , Francesco Giardino  3 , Stefania Nicola  4 , Riccardo Senter  1 , Paola Triggianese  5 , Sherry Danese  6 , Julie Ulloa  6 , Vibha Desai  7 , Joao P Frade  7 , Paul K Audhya  7 , Andrea Zanichelli  8   9 ; ITACA Group
Collaborators, Affiliations

Delays and Barriers Related to the Treatment of Hereditary Angioedema Attacks in Italy

Mauro Cancian et al. Allergy. 2025 Nov.
No abstract available

Keywords: ITACA; hereditary angioedema; on‐demand treatment; treatment barriers; treatment delay.

PubMed Disclaimer

Conflict of interest statement

M.C. has received honoraria and/or meeting/travel support from BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis, Pharvaris, Sanofi, SOBI, and Takeda. F.G. has served on advisory boards/seminars funded by BioCryst, CSL Behring, KalVista Pharmaceuticals, and Takeda and has received funding from CSL Behring and Takeda to attend conferences/educational events. R.S. has served as a consultant for BioCryst, KalVista Pharmaceuticals, and Takeda and has received travel grants from Alk Abello, BioCryst, CSL Behring, Novartis, and Takeda. P.T. was a speaker/consultant for and received honoraria and/or meeting/travel support from AbbVie, Janssen, BioCryst, CSL Behring, KalVista Pharmaceuticals, Novartis, and Takeda. S.D. and J.U. have received consulting fees from KalVista Pharmaceuticals. V.D. is a former salaried employee of KalVista Pharmaceuticals. J.P.F. and P.K.A. are salaried employees of KalVista Pharmaceuticals. P.A., F.A., S.N., and A.Z. have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Peak attack severity* by time to OD. *Attack severity was graded by patients using a 4‐point Likert scale, where 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe. Because of rounding, percentages may not total 100%. OD, on‐demand treatment.
FIGURE 2
FIGURE 2
Top‐5–ranked barriers to not treating attacks sooner. Data based on the responses of the 81 respondents who did not immediately treat their last attack. *In four patients, the last treated attack presented in other locations (genitals, n = 3; other, n = 1). Because of the small sample sizes, data from these subgroups are not presented. Because of rounding, percentages may not total 100%. IV, intravenous; LTP, long‐term prophylaxis; OD, on‐demand treatment; SC, subcutaneous.
See this image and copyright information in PMC

References

    1. Betschel S., Badiou J., Binkley K., et al., “The International/Canadian Hereditary Angioedema Guideline,” Allergy, Asthma and Clinical Immunology 15 (2019): 72, 10.1186/s13223-019-0376-8. - DOI - PMC - PubMed
    1. Maurer M., Magerl M., Betschel S., et al., “The International WAO/EAACI Guideline for the Management of Hereditary Angioedema‐The 2021 Revision and Update,” Allergy 77, no. 7 (2022): 1961–1990, 10.1111/all.15214. - DOI - PubMed
    1. Betschel S. D., Caballero T., Jones D. H., et al., “The Complexities of Decision‐Making Associated With On‐Demand Treatment of Hereditary Angioedema (HAE) Attacks,” Allergy, Asthma and Clinical Immunology 20, no. 1 (2024): 43, 10.1186/s13223-024-00903-w. - DOI - PMC - PubMed
    1. Christiansen S., O'Connor M., Craig T., et al., “On‐Demand Treatment of Hereditary Angioedema Attacks: Patient‐Reported Utilization, Barriers, and Outcomes,” Annals of Allergy, Asthma & Immunology 134, no. 5 (2025): P570–579.E4, 10.1016/j.anai.2024.12.012. - DOI - PubMed
    1. Lumry W. R., Grumach A. S., Betschel S. D., et al., “Management of Hereditary Angioedema Attacks by Patients on Long‐Term Prophylaxis Versus On‐Demand Therapy Only,” Allergy and Asthma Proceedings 46, no. 1 (2025): 32–37, 10.2500/aap.2025.46.240096. - DOI - PubMed